-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
DICE Therapeutics, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q2 2021 to Q2 2023.
- DICE Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending June 30, 2023 was -0.74 USD/shares, a 27.6% decline year-over-year.
- DICE Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending June 30, 2023 was -2.33 USD/shares.
- DICE Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was -2.13 USD/shares, a 46.1% increase from 2021.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)